The Veterinary POCT Market: Size, Trends & Drivers¶
The veterinary point-of-care testing (POCT) market is one of the fastest-growing segments in animal health. This page summarizes the market structure and the forces driving it.
Market Structure¶
| Segment | Description |
|---|---|
| Companion animal | Dogs, cats — the dominant POCT segment |
| Livestock | Production animals — herd health testing |
| Exotic / specialty | Birds, reptiles, equine |
Growth Drivers¶
| Driver | Why it matters |
|---|---|
| Pet humanization | Owners expect the same care standards as human medicine |
| In-clinic economics | Same-visit results generate revenue and retention |
| Technology shift | Quantitative POCT displacing qualitative strips |
| Aging pet population | Chronic disease (kidney, cardiac) demands monitoring |
The Quantitative Shift¶
The market is moving from qualitative (line-based) to quantitative (instrument-read) testing — the same transition human POCT underwent a decade earlier. FICT is positioned at the leading edge of this shift.
Competitive Landscape¶
| Category | Examples |
|---|---|
| Global reference labs | IDEXX, Zoetis (Abaxis) |
| Instrumented POCT | Migibio FICT, others |
| Qualitative strips | Commodity manufacturers |
FAQ¶
Why is quantitative POCT displacing strips? Numbers enable staging, monitoring, and threshold decisions that qualitative strips cannot — the same reason human POCT went quantitative.
What is the key adoption barrier? Instrument cost and staff training — which is why workflow design (see POCT Workflow) matters.
For the technology roadmap, see Technology Roadmap.
Authored by: Migibio Clinical & Scientific Affairs, Guangzhou Magic Biotech Co., Ltd.
Reviewed by: Migibio R&D Quality Committee
Last updated: 2026-08-13
Disclosure: Migibio (Guangzhou Magic Biotech Co., Ltd.) is the manufacturer of the FIA680/FIA880 analyzers and FICT reagents referenced in this content. See our Editorial & Review Policy.